That's a great question! Based on available research, GLP-1 receptor agonists don't currently appear in the pipeline of treatments being studied specifically for PBC.
The emerging treatments being investigated for PBC are focused on different mechanisms. Here's what's currently in clinical trials or recently approved:
- Show Full Answer
That's a great question! Based on available research, GLP-1 receptor agonists don't currently appear in the pipeline of treatments being studied specifically for PBC.
The emerging treatments being investigated for PBC are focused on different mechanisms. Here's what's currently in clinical trials or recently approved:
- Setanaxib – a NOX inhibitor that may slow liver scarring
- Linerixibat & Volixibat – IBAT inhibitors targeting itching
- CNP-104 – a nanoparticle therapy aimed at retraining the immune system
- Elafibranor (Iqirvo) & Seladelpar (Livdelzi) – already FDA-approved PPAR agonists
- Fibrates – being studied for both disease progression and itch relief Since PBC is an autoimmune condition affecting the bile ducts rather than a metabolic liver condition, researchers are focusing on treatments that target bile acid regulation, liver inflammation, and immune system activity.
It's always worth asking your hepatologist directly — they'll have the most current knowledge of any newly emerging trials that might be relevant to your specific situation.
August 3
Join
Your Privacy Choices
